Meptazinol
- N02AX05 (WHO)
- AU: S4 (Prescription only)
- UK: POM (Prescription only)
- (RS)-3-(3-Ethyl-1-methylazepan-3-yl)phenol
- 54340-58-8 Y
- HCl: 59263-76-2 Y
- 41049
- 37469 Y
- 18Y7S5JKZD
- HCl: T62FQ4ZCPA Y
- D08182 Y
- ChEMBL314437 Y
- DTXSID6048543
- Interactive image
- OC1=CC=CC(C2(CCCCN(C2)C)CC)=C1
- InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3 Y
- Key:JLICHNCFTLFZJN-UHFFFAOYSA-N Y
Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s.[1] Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth).
Meptazinol is a 3-phenylazepane derivative, whereas the other phenazepanes like ethoheptazine and proheptazine are 4-phenylazepanes.
A partial μ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full μ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.[2]
References
- ^ US patent 4197239, Cavalla JF, Shepherd RG, White AC, "Hexahydroazepine, Piperidine and Pyrrolidine Derivatives", issued 1980-04-08, assigned to Wyeth
- ^ Holmes B, Ward A (1985). "Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy". Drugs. 30 (4): 285–312. doi:10.2165/00003495-198530040-00001. PMID 2998723. S2CID 208818234.
External links
- Meptazinol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- v
- t
- e
modulators
Calcium blockers |
|
---|---|
Sodium blockers |
|
Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e